4.7 Article

Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease

期刊

NEUROLOGY
卷 78, 期 6, 页码 379-386

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e318245f447

关键词

-

资金

  1. German Ministry of Research (Bundesministerium fur Bildung und Forschung) [01GI0420]
  2. German Ministry of Education and Research (BMBF)
  3. German Research Foundation (DFG)
  4. UCB
  5. Novartis
  6. BfArM
  7. Pfizer Inc/Wyeth
  8. Medivation, Inc.
  9. BMG WHEDA
  10. Allergan, Inc.
  11. Eisai Inc.
  12. Elan Corporation/Wyeth
  13. Janssen
  14. Lundbeck, Inc.
  15. Merz Pharmaceuticals, LLC
  16. Neurochem Inc.
  17. Pfizer Inc.
  18. BRAHMS AG
  19. GlaxoSmithKline
  20. State of Hess, Germany
  21. Katharina-Hardt-Foundation
  22. Thea-Goring-Foundation
  23. AC Immune SA
  24. AFFiRiS AG
  25. Bayer Schering Pharma
  26. Bristol-Myers Squibb
  27. Eli Lilly Company
  28. Pfizer Inc
  29. Roche
  30. Servier
  31. Wyeth
  32. European Union ERA-NET Neuron
  33. Innogenetics
  34. Siemens Health Care
  35. Bayerische Forschungsstiftung (BFS)

向作者/读者索取更多资源

Objective: To compare cued recall measures with other memory and nonmemory tests regarding their association with a biomarker profile indicative of Alzheimer disease (AD) in CSF among patients with mild cognitive impairment (MCI). Methods: Data were obtained by the German Dementia Competence Network. A total of 185 memory clinic patients fulfilling broad criteria for MCI (1 SD deficit in memory tests or in nonmemory tests) were assessed with an extended neuropsychological battery, which included the Free and Cued Selective Reminding Test (FCSRT), the word list learning task from the Consortium to Establish a Registry for Alzheimer's Disease neuropsychological battery (CERAD-NP), and the Logical Memory (LM) paragraph recall test from the Wechsler Memory Scale-Revised. CSF was obtained from all patients. Results: A total of 74 out of 185 subjects with MCI (40%) had a CSF profile consistent with AD (A beta(1-42)/tau ratio; CSF AD + group). FCSRT measures reflecting both free and cued recall discriminated best between CSF AD + and CSF AD - patients, and significantly improved CSF AD classification accuracy, as compared with CERAD delayed recall and LM delayed recall. Conclusions: Cued recall deficits are most closely associated with CSF biomarkers indicative of AD in subjects with MCI. This novel finding complements results from prospective clinical studies and provides further empirical support for cued recall as a specific indicator of prodromal AD, in line with recently proposed research criteria. Neurology (R) 2012; 78: 379-386

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据